# Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study

> **NCT05532852** · NA · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 728 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** standard-of-care plus Paxlovid
- **DRUG:** standard-of-care

## Key facts

- **NCT ID:** NCT05532852
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-06
- **Final completion:** 2023-10
- **Target enrollment:** 728 (ESTIMATED)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532852, "Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05532852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*